まとめ
原因XI欠乏症の患者は,長期の出血リスクにもかかわらず,肺栓塞を発症することがあります. 静脈栓塞の予防プログラムは,これらの患者にとって不可欠です. 出血障害の術前スクリーニングは,すべての手術患者のために非常に重要です.
科学分野:
- 血液学 ヘマトロジ
- 血管医学 血管医学とは
- トロンボシス研究研究
背景:
- 因子XI欠乏症は,珍しい遺伝性出血障害である.
- 手術後の静脈血栓塞栓症 (VTE) は,重要な臨床的懸念事項です.
- 低用量のヘパリンは,一般的にVTE予防に使用されます.
研究 の 目的:
- 重度のXI因子欠乏症の患者における肺栓塞のリスクを調査する.
- 要素XI欠乏症の患者における静脈血栓形成の標準的な予防の有効性を評価する.
主な方法:
- 重度の因子XI欠乏症の患者の症例報告.
- 患者の術後経過と合併症の分析.
- 因子XI欠乏症と血栓形成に関する既存の文献のレビュー.
主要な成果:
- 患者のXI因子活性が1%未満であった患者は,術後肺栓塞を発症した.
- 患者は,因子XI欠乏症と一致する長時間出血を経験しました.
- 欠陥状態は静脈性血栓塞栓症に対する保護を与えなかった.
結論:
- 素因子XIの欠乏は肺栓塞を予防するものではありません.
- 静脈栓塞の予防戦略は,手術を受けるXI因子欠乏症の患者で実施すべきである.
- 低用量のヘパリンを投与されているすべての手術患者の場合,未診断の出血障害を検出するために,部分性血栓形成時間による術前スクリーニングが推奨されます.
関連する概念動画
Acute Respiratory Failure-II
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
Pneumothorax-I
A pneumothorax is a condition where air builds up in the space between the lung and the chest wall, causing the lung to collapse. This condition arises when air enters the space between the parietal and visceral pleura, disrupting the negative pressure essential for lung inflation. This can lead to a partial or complete collapse of the lung.
Pneumothorax can be even further classified as spontaneous, traumatic, and tension pneumothorax.
Pneumothorax can be even further classified as spontaneous, traumatic, and tension pneumothorax.
Atelectasis II: Pathophysiology
Atelectasis develops when alveoli lose their air and collapse inward. Because lung tissue is naturally elastic, these air sacs shrink rather than remaining open. Collapsed alveoli are no longer ventilated, reducing their role in gas exchange. Blood flow may continue in these regions, creating a ventilation–perfusion mismatch. Clinical findings include decreased breath sounds, dullness to percussion, reduced chest expansion, and decreased tactile fremitus as sound transmission through collapsed...
Chronic Obstructive Pulmonary Disease II: Emphysema
Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
Pulmonary Edema II: Pathophysiology
Pulmonary edema is the accumulation of fluid in the interstitial and alveolar spaces of the lungs, impairing gas exchange and oxygen delivery. It may be cardiogenic or noncardiogenic, but both reduce oxygenation and lung compliance.Cardiogenic Pulmonary EdemaCardiogenic edema results from increased hydrostatic pressure in pulmonary capillaries, usually due to left ventricular dysfunction from myocardial infarction, heart failure, or valvular disease. Ineffective cardiac pumping causes blood to...


